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ABSTRACT
Hepatitis C virus (HCV) is a major cause of chronic liver
disease, with about 170 million people infected world-
wide. Up to 70% of patients will have persistent infection
after inoculation, making this disease a significant cause
of morbidity and mortality.
The severity of disease varies widely, from asymptomatic
chronic infection to cirrhosis and hepatocellular carci-
noma. Since the discovery of HCV, the treatment of
hepatitis C has considerably improved. Recently, combi-
nation of pegylated interferons with ribavirin gives a
response rate of about 55%. Treatment is indicated in
patients with moderate or severe fibrosis. The tolerability
of combination treatment is relatively poor, with a
frequent flu-like syndrome and an impaired quality of life.
In addition to viral and environmental behavioural factors,
host genetic diversity is believed to contribute to the
spectrum of clinical outcomes in HCV infection. The
sequencing of the human genome, together with the
development of high-throughput technologies that mea-
sure the function of the genome, have afforded unique
opportunities to develop profiles that can distinguish,
identify and classify discrete subsets of disease, predict
the disease outcome or predict the response to
treatment. This paper reviews the published literature on
gene expression associated with HCV infection (HCV
infection, fibrosis progression), and also according to
response to treatment.
PATHOPHYSIOLOGY
Hepatitis C virus (HCV) is a major cause of chronic
liver disease, with ,170 million people infected
worldwide
1 (box 1). HCV belongs to the
Flaviviridae family (hepacivirus genus), and is an
enveloped virus with a 9.6 kb single-stranded RNA
genome
2–7 (box 2). Until recently, the absence of a
cell culture model supporting full replication of
HCV and of convenient animal models has limited
knowledge of the HCV life cycle and the testing for
antiviral molecules. The chimpanzee is the only
animal model for HCV infection.
8 The develop-
ment of a subgenomic HCV RNA replicon capable
of replication in the human hepatoma cell line,
Huh 7, was a significant advance.
91 0 Recently,
complete replication of HCV in cell culture has
been achieved.
11 12 These models will improve our
understanding of HCV replication and the testing
for antiviral molecules. HCV infection is associated
with a spectrum of extrahepatic manifestations,
mainly mixed cryoglobulin.
13
INTERFERON SIGNALLING AND HCV INFECTION
Endogenous type I interferons (IFNs) are the main
antiviral cytokines. HCV infection may activate
host signalling pathways that induce type I IFNs.
14–16
It should be remembered that the double-stranded
(ds) RNA virus induces the host immune response;
dsRNA which is a pathogen-associated molecular
pattern, is recognised by pattern recognition recep-
tors (PRRs) such as Toll-like receptor 3 (TLR3) and
retinoic acid-inducible gene-I (RIG-I) (fig 1).
Although HCV is a single-stranded RNA, the fact
that replication of the HCV genome is catalysed by
its RNA-dependent RNA polymerase, NS5B, sug-
gests that dsRNA may be formed during the HCV
life cycle and activate PRRs. Activation of TLR3 via
the adaptor TRIF leads to phosphorylation of IFN
regulatory factor-3 (IRF-3) and activation of tran-
scriptionfactorsAP-1andnuclearfactor-kB(N F- kB).
Phosphorylated IRF-3 forms a dimer, translocates
into the nuclei, binds to DNA and regulates the
expression of IFNb expression in collaboration
with AP-1 and NF-kB. After recognition of viral
RNA, RIG-I and Mda5 recruit IFNb promoter
stimulator-1 (IPS-1, also known as Cardif).
15 IPS-1
is localised to mitochondria and plays a critical role
in the activation of IRF-7, IRF-3 and NF-kB. IRF-7
forms a dimer, translocates into the nucleus to
induce IFNa/b; homodimers of IRF-3 collaborate
with NF-kBt oi n d u c eI F N b.I F N a/b of autocrine/
paracrine sources bind to a common receptor
expressed at the cell surface. Receptor engagement
causes the activation of Jak (Janus kinase)–STAT
(signal transducers and activators of transcription)
signalling which, together with ISGF3G (IFN-
stimulated gene factor 3, c subunit)/IRF-9, binds to
IFN-stimulated response elements (ISREs), thereby
activating the transcription of IFNa/b-inducible
genes.
14 This results in the production of effector
molecules, such as RNase L and protein kinase R
(PKR), that will degrade viral RNAs and block their
translation.
It should be noted that HCV RNA encodes
specific proteins that may inhibit the induction of
type I IFNs. An example is the NS3-4A protease of
HCV, which blocks dsRNA-induced IFN production
byinterfering with IRF-3 phosphorylation.
16 NS3-4A
cleaves the C-terminal region of IPS-1/Cardif, caus-
ing disruption of NF-kB and IRF-3 activation,
probably due to mislocalisation of cleaved IPS-1/
Cardif from mitochondria. NS3-4A also mediates
TRIF proteolysis, suggesting multiple functions for
this protease. Thus, HCV proteins may block both
the TLR- and RIG-I–Mda5-dependent signalling
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the NS3-4A protease is a dual therapeutic target,
whose inhibition may block viral replication and
restore IRF-3 control of HCV infection.
HCV-related effects may also attenuate IFN
signalling. Proteins called suppressor of cytokine
signalling (SOCS) are known to inhibit cytokine
signalling via Jak–STAT. The HCV core protein
has been shown to induce the expression of
SOCS3, which can suppress Jak–STAT signalling
events and block the IFN-induced formation of
ISGF3.
17 HCV protein expression in liver cells is
associated with induction of the protein inhibitor
of activated STAT (PIAS) expression and inhibition
of STAT function. Patients with chronic HCV
infection have been shown to exhibit high levels of
interleukin 8 (IL8) in the liver.
18 The biological
activity of IL8 interferes with IFN signalling events
that result in ISGF3 recruitment and function.
Together, these findings suggest that HCV
modulation of IFN induction and signalling limits
the expression of IFN-stimulated genes, allowing
HCV to evade the antiviral actions of the host
response.
MICRORNA AND HCV INFECTION
MicroRNAs (miRNAs) are a class of small non-
coding RNA molecules of 20–22 nucleotides that
control gene expression by targeting mRNAs for
translational repression or cleavage.
19 The biogen-
esis of miRNAs involves a complex protein system,
including RNA polymerase II and the RNase IIIs
Drosha and Dicer (fig 2). A total of nearly 700
human miRNAs have been reported so far (the
April 2008 release of miRBase Sequence Database-
Release 11.0, at the Sanger Institute), but a total
number of .1000 human miRNAs is estimated.
20
miRNAs are a new player among gene regulation
mechanisms and, although their functions have
not been fully clarified, they include the regulation
of development, cell differentiation, proliferation
and apoptosis.
Silencing of the RNAase III Dicer has been
shown to inhibit HCV replication by ,7-fold.
21
Moreover, depletion of Huh7 hepatoma of the
liver-specific miRNA miR-122 (that directly inter-
acts with the 59 end of the HCV RNA genome)
was found to be associated with inhibition of
HCV replication and infectious viral production.
22
These findings suggest that HCV takes advantage
of the presence of miR-122 in hepatocytes, which
may be a target for novel approaches in the
treatment of HCV infection. Interestingly, IFNb
was found to modulate the expression of
numerous cellular miRNAs rapidly in vitro, and
eight of these IFNb-induced miRNAs were shown
to have sequence-predicted targets within the
HCV genomic RNA.
23 Moreover, IFNb results in a
significant reduction in miR-122 expression.
These findings strongly support the notion that
the human organism uses cellular miRNAs to
combat HCV infection through the IFN system,
and also adds a new component to the antiviral
arsenal of IFNs, which are the most common
treatment of HCV infection.
HCV IN HUMAN LIVER SAMPLES: CONTRIBUTION
FROM GENE EXPRESSION STUDIES
The recent development of efficient tools for large-
scale analysis of gene expression has provided new
insights into the role of gene networks and
regulatory pathways in various tumour processes.
24
These tools include microarrays, which can analyse
the expression of thousands of genes at one time,
and real-time reverse transcription-PCR (RT-PCR)
assays for more accurate and quantitative expres-
sion analysis of smaller numbers of candidate
genes.
18
Little is known about the molecular mechanisms
associated with HCV infection in humans. Liver
gene expression was studied, by large-scale real-
time RT-PCR, in patients with untreated chronic
hepatitis C and mild fibrosis compared with
histologically normal controls.
25 The most signifi-
cant changes in gene expression mainly affected
the transcriptional network regulated by IFNs,
including both IFNa/b-inducible genes (STAT1,
STAT2, ISGF3G/IRF9, IFI27, G1P3, G1P2, OAS2
and MX1) and IFNc-inducible genes (CXCL9,
Box 1 Natural history of hepatitis C virus infection
The natural history of hepatitis C virus infection is influenced by both genetic and
environmental factors. T lymphocytes, which are important in terms of both viral
clearance and hepatotoxicity, are stimulated in their response after presentation
of foreign material by antigen-presenting cells in association with major
histocompatibility complex (MHC) molecules. Several studies, predominantly in
Caucasians, have found associations of the human leucocyte antigen (HLA) class
II alleles DQB1 0301 and DRB111 with self-limiting infection populations. Also a
high quasispecies population is believed to be associated with chronicity.
The major factors known to be associated with fibrosis progression are male
gender, older age at infection and excessive alcohol consumption. Interestingly,
viral factors such as viral load and genotype do not seem to influence the
progression rate significantly. Progression of fibrosis is more rapid in
immunocompromised patients. Insulin resistance may also contribute to more
rapid progression of fibrosis.
31–33
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genes was mainly HCV specific (no upregulation
in hepatitis B virus (HBV) infection).
Interestingly, similar results were found in a
recent DNA microarray analysis in nine individuals
with chronic hepatitis C compared with non-
diseased liver controls.
26 A significant proportion of
upregulated genes in chronic hepatitis C were
potential ISGs, suggesting an ongoing response to
endogenousIFNand/ordsRNA.Viperin,anevolutio-
narily conserved ISG with antiviral activity against
humancytomegalovirus,wassignificantlyelevatedin
all patients. When Huh7 and HepG2 cells were
stimulation with IFNa or IFNc, viperin was shown
to bea predominantlyatypeI ISG.Furthermore,ISG
viperin had anti-HCV activity in vitro.
THE PROGRESSION OF FIBROSIS IN HEPATITIS C
AND EXISTING PREDICTIVE FACTORS
Liver fibrosis is the accumulation in excess of
extracellular matrix proteins including collagen.
27
Fibrogenesis is a complex dynamic process,
mediated by necroinflammation and the activation
of stellate cells (fig 3). The progression of fibrosis in
chronic hepatitis C determines the ultimate prog-
nosis and thus the need for and urgency of
treatment.
2829 Liver biopsy remains the gold stan-
dard to assess fibrosis (fig 4). Scoring systems
(Knodell, Metavir, Ishak, etc.) provide a semi-
quantitative assessment for individual clinical
prognosis, cross-sectional and cohort studies, and
treatment trials.
30 The major factors associated
with the progression of fibrosis are male gender,
older age at infection, excess alcohol consumption
and immunosuppression.
31 32 Insulin resistance
may also play a role in the more rapid progression
of fibrosis.
33 The natural history of liver fibrosis in
chronic hepatitis C is influenced by both genetic
and environmental factors (box 1).
In a recent study, Strnad et al analysed genomic
DNA from a well-characterised German cohort of
329 patients with chronic hepatitis C and found
that previously described and novel keratin 8 (K8)
variants are present and collectively associate with
the progression of fibrosis.
34 The unique 100%
segregation of the most common K8 variant,
R341H, with an intronic deletion suggests that
one of these two genetic changes might lead to the
other. One potential mechanism which may cause
K8 and K18 variants to predispose to liver injury is
their established role in hepatocyte cytoprotection,
which has been clearly documented in several
transgenic mouse studies that express K8/K18
mutants or that lack K8/K18.
35
LARGE-SCALE AND GENOME-WIDE ASSOCIATION
STUDIES IN THE PROGRESSION OF FIBROSIS
Until recently, almost all association studies
performed to identify genetic variants associated
with HCV clearance, the progression of fibrosis or
the response to antiviral treatment have focused on
variations in one or a few candidate genes, chosen
on the basis either of their known function or from
animal models. Recent advances in high-through-
put genotyping technology have now made large-
scale association studies a reality, and the number
of candidate genes investigated in each study is
rapidly increasing.
Genome-wide association studies (GWAS) are
now ongoing thanks to the rapidly decreasing cost
of genotyping, massively multiplexed genotyping
technologies, large-scale single nucleotide poly-
morphism (SNP) discovery as well as the genotyp-
ing efforts of the SNP Consortium and the
HapMap project. GWAS use dense maps of genetic
markers that cover the human genome to look for
allele frequency differences between cases and
controls. A significant frequency difference sug-
gests that the corresponding region of the genome
contains functional DNA variants that influence
the trait of interest. The candidate gene strategy
Box 2 HCV cycle
HCV is a member of the Flaviviridae family, genus Hepacivirus. Error-prone
replication of HCV, resulting in a complex quasispecies population within each
infected individual, enables rapid adaptation to changing environments. Six HCV
genotypes and a large number of subtypes have been identified.
3 The HCV virion
is made of a single-stranded positive RNA genome, contained in a capsid, itself
enveloped by a lipid bilayer within which two different glycoproteins are
anchored. The HCV life cycle starts with virion attachment to its specific receptor.
Several candidate molecules have been suggested to play a role in the receptor
complex, including tetraspanin CD81, the scavenger receptor BI (SR-BI), the
adhesion molecules DC-SIGN and L-SIGN, and the low-density lipoprotein (LDL)
receptor.
4 Recently, the tight junction components claudins (mainly CLDN-1,
CLDN-6 and CLDN-9) have been identified as additional key factors for HCV
infection.
56The CD81 partner EWI-2wint inhibits HCV entry, suggesting that, in
addition to the presence of specific entry factors in the hepatocytes, lacko fa
specific inhibitor can contribute to the hepatotropism of HCV.
7 The HCV RNA
genome serves as a template for viral replication and as a viral mRNA for viral
production. It is translated into a polyprotein which is cleaved by proteases.
8–10
All the HCV enzymes—NS2-3 and NS3-4A proteases, NS3 helicase and NS5B
RdRp—are essential for HCV replication, and are therefore potential drug
discovery targets.
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manageable number of genes and polymorphisms
that are likely to be important. The strength of the
genome-wide screening is its ability to reveal not
only genes that would be expected to play a
significant role, but also genes that would not,
potentially adding new insight into pathophysiol-
ogy or pharmacology.
A genome-wide scan with putative functional
SNPs was carried out on a group of 433 HCV
patients (discovery cohort); those markers asso-
ciated with advanced fibrosis were validated in a
separate group of 483 patients (replication
cohort).
36 This functional genome scan included
24 823 gene-centric SNPs composed of either
coding functional SNPs (missense, nonsense,
acceptor and donor splice sites) or non-coding
putative regulatory SNPs that may effect RNA
stability (SNPs located at putative transcription
factor-binding sites, or 59-/39-untranslated regions).
A total of 12 248 genes were directly covered by
the scan. Most genes were tested with only one
SNP; however, 1418 genes had >4 SNPs. Of the
24 823 SNPs genotyped in the discovery cohort,
Figure 1 Hepatitis C virus (HCV) infection and immune response. HCV can induce several signalling pathways. (A) Toll-like receptor (TLR) signalling.
Activation of TLR3 leads to the recruitment of IkB kinase (IKK)-related kinases, TANK-binding kinase 1 (TBK1, also known as T2K and NAK) and IKKi
(also known as IKKe). These kinases, together with adaptors TANK and NAP1, catalyse the phosphorylation of interferon (IFN) regulatory factor-3 (IRF-
3). TLR3 engagement also results in the activation of transcription factors AP-1 and nuclear factor-kB (NF-kB). Phosphorylated IRF-3 forms a dimer,
translocates into the nuclei, binds to DNA and regulates the expression of IFNb in collaboration with AP-1 and NF-kB. The HCV NS3-4A serine protease
may block the phosphorylation and effector action of IRF-3. (B) Retinoic acid-inducible gene-I (RIG-I)-like RNA helicase signalling. After recognition of
viral RNA, RIG-I and also Mda5 (not shown) recruit IFNb promoter stimulator-1 (IPS-1, also known as MAVS, Cardif and VISA) via CARD–CARD
(caspase recruitment domain) interaction. IPS-1 is localised to mitochondria and acts as an adaptor that plays a critical role in the activation of IRF-3
and IRF-7 in a TBK1- and IKKi-dependent manner. IPS-1 also interacts with the Fas-associated death domain protein (FADD), which is required for the
activation of IRF-3 and NF-kB. IRF-7 forms a dimer, translocates into the nucleus to induce IFNa/b; homodimers of IRF-3 collaborate with NF-kBt o
induce IFNb. IPS-1 is targeted and inactivated by NS3-4A, a serine protease from HCV known to block IFNb production. (C) IFN signalling. Endogenous
IFNa/b bind to a common receptor expressed at the surface of target cells. Receptor engagement leads to the activation of STAT1 (signal transducer
and activator of transcription 1) and STAT2, which, together with ISGF3G (IFN-stimulated gene factor 3, c subunit)/IRF-9, bind to cis-acting IFN-
stimulated response elements (ISREs) (D), thereby activating the transcription of IFNa/b-inducible genes such as those encoding RNase L and protein
kinase R (PKR) which degrade viral RNAs and block their translation. Also, the HCV core protein has been shown to induce the expression of SOCS3
(suppressor of cytokine signalling 3), which can suppress Jak (Janus kinase)–STAT signalling events and block the IFN-induced formation of ISGF3.
58
PAMP, pathogen-associated molecular pattern.
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advanced fibrosis. Of these, 438 SNPs (27.2%) had
odds ratios (ORs) .2o r,0.5. The first 100
consecutive SNPs found to be associated with
advanced fibrosis in this cohort were then vali-
dated by individual genotyping in the replication
cohort to confirm the observed associations. Two
of these 100 SNPs were found to be significantly
associated with advanced fibrosis in both cohorts,
with ORs of similar magnitude and direction. The
first one was a missense SNP in the DEAD box
polypeptide 5 (DDX5) gene which was signifi-
cantly associated with an increased risk of
advanced fibrosis in both the discovery and
replication cohorts (OR, 1.8 and 2.2, respectively).
The second one was a missense SNP in the
carnitine palmitoyltransferase 1A (CPT1A) gene
associated with a decreased risk of advanced
fibrosis in both the discovery and replication
cohorts (OR, 0.3 and 0.6, respectively). These
two novel markers could play a useful role in
predicting risk of fibrosis in HCV patients. After
the initial findings of two replicated SNPs, the
confirmation of all significant SNPs from their
genomic scan was completed and 361 SNPs were
selected for signature building.
37 A machine learn-
ing tool developed a predictive signature for
cirrhosis in Caucasian patients. A seven gene
signature that accurately differentiated high risk
versus low risk for cirrhosis was developed using
WEKA, an open source Machine Learning
Workbench.
38
CONTRIBUTION OF GENE EXPRESSION STUDIES IN
THE PROGRESSION OF FIBROSIS
In chronic hepatitis C, the transition from mild to
moderate fibrosis seems to be a major prognostic
step. Several consensus conferences have proposed
that patients with mild fibrosis might not be
treated because their prognosis is good.
12 82 9When
the area of fibrosis is assessed by image analysis,
the transition from moderate to severe fibrosis is
associated with a marked increase in the area of
fibrosis.
39
In a previous study to identify molecular
markers of prognosis in chronic hepatitis C,
mRNA expression was quantified by real-time
quantitative RT-PCR in a large number of selected
genes in F2 (moderate fibrosis) specimens and
compared with F1 (mild fibrosis) specimens.
18
Genes involved in the physiology of fibrosis were
selected (box 3). Twenty-two genes were identified
that were upregulated in the F2 samples compared
with the F1 samples. These upregulated genes
mainly encoded genes involved in the cytoskeleton
(KRT19 and SCG10), growth factors/cytokines
(CXCL6, IL8, IL1A, IL2 and CXCL10), growth
factor receptors (CCR2, CXCR3 and CXCR4), in
extracellular matrix production (COL1A1, CHI3,
and SPP1), in extracellular matrix remodelling
(TIMP1, MMP7 and MMP9) and in the cell
junction (ITGA2 and CLDN4)(table 1).
Interestingly, a recent study has demonstrated
that histologically normal liver tissue obtained in
two different ways (ie, percutaneous or surgical
liver biopsies) has different gene expression pat-
terns although all specimens are histologically
normal.
40 The most notable changes in gene
expression occurred in the inflammatory response
gene family. These results emphasise the impor-
tance of an adequate selection of histologically
normal controls to prevent discordant or false
results in gene expression profile analysis.
Although it is difficult to state which is the best
‘‘histologically normal’’ control, when performing
studies, histologically normal controls should
always be obtained by the same technique as
pathological samples. For instance, in chronic
hepatitis C studies, where liver samples are
obtained percutaneously, the ‘‘histologically nor-
mal’’ samples should also be obtained by percuta-
neous liver biopsy. Controls should always be
clearly described. Finally, the careful selection of
controls is crucial because inappropriate samples
could lead to misinterpretation of results.
Finding molecular markers of the progression of
fibrosis has several clinical implications. First,
many of the genes found to be upregulated
between mild and moderate fibrosis encode mole-
cules secreted in the serum (cytokines). Therefore,
looking for genes dysregulated in the liver can
constitute a logical functional approach for the
discovery of serum markers of the progression of
fibrosis. For example, serum levels of cytokines
Figure 2 Biogenesis of microRNAs (miRNAs). miRNA is transcribed mainly by RNA
polymerase II. The primary transcript (pri-miRNA that can be quite large) is processed in
the nucleus by an enzymatic complex that includes the enzymes Drosha and DGCR8,
which leads to the formation of a 70–100 nucleotide hairpin precursor named pre-miRNA.
This second precursor binds exportin-5 in the nucleus and is transported to the
cytoplasm, where it is cleaved by Dicer into mature miRNA. This mature miRNAi s
incorporated into a ribonucleoprotein complex called the ‘‘RNA-induced silencing
complex’’ (RISC), and guides the RISC to the 39-unstranslated region of the target
mRNAs. On the basis of the degree of homology between the miRNA and the mRNA,
RISC can inhibit mRNA function by either promoting its degradation or inhibiting its
translation. It is believed that each miRNA can target up to 200 mRNAs, and multiple
miRNAs can target a given transcript. Therefore, the potential regulatory circuitry
afforded by miRNA is extremely complex.
Recent advances in basic science
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chronic hepatitis C. Secondly, since a primary goal
in the treatment of HCV infection is eradication of
the virus and another is to stop the progression of
fibrosis, molecular markers of the progression of
fibrosis could help define new endpoints during
antiviral treatment. Therefore, gene changes could
be new markers of the progression of fibrosis
during antiviral treatment. Thirdly, many of the
upregulated genes identified in this gene expression
study are potential molecular targets for the
development of antifibrotic drugs.
EPIGENOMICS OF HCV-INDUCED LIVER FIBROSIS
An altered pattern of epigenetic modifications is
central to many common human diseases, includ-
ing cancer
41 (box 4). Although there are numerous
aspects of epigenetic gene silencing, this review
will focus on promoter CpG island hypermethyla-
tion, the major research area (epigenetic gene
silencing) in HCV-induced liver fibrosis.
Tools for large-scale analysis of CpG island
hypermethylation include array-based epigenomic
analysis methods such as DHM (differential
methylation hybridisation) for a genome-wide
screening of CpG island hypermethylation (DNA
methylome) or large-scale quantitative real-time
PCR-based methylation analysis methods for more
accurate and quantitative analysis of DNA methy-
lation of specific candidate genes.
42
There are only a few studies in the literature on
array-based epigenomic analysis and the early
stages of liver fibrosis associated with chronic
HCV infection. Gao et al
43 reported CpG island
methylation at the genomic level in adjacent
preneoplastic liver tissues (chronic hepatitis and
liver cirrhosis) of 38 hepatocellular carcinoma
(HCC) patients with HCV infection (n=15),
HBV infection (n=11), both (n=1) or without
Figure 3 The stellate cell: a key cell implicated in fibrogenesis. Hepatic stellate cells
(HSCs) exist in the space between parenchymal cells and sinusoidal endothelial cells of
the hepatic lobule, and store vitamin A as retinyl palmitate in lipid droplets in the
cytoplasm. In physiological conditions, these cells play pivotal roles in the regulation of
vitamin A homeostasis; they express specific receptors for retinol-binding protein (RBP),
a binding protein specific for retinol, on their cell surface, and take up the complex of
retinol and RBP by receptor-mediated endocytosis. In a normal state, HSCs appear as
quiescent vitamin A-storing cells. When activated via several stimuli (infection, alcohol,
cytokines, etc.) they acquire a proliferative myofibroblast phenotype. In pathological
conditions such as chronic hepatitis C, HSCs lose vitamin A and synthesise a large
amount of extracellular matrix components including collagen, proteoglycan and adhesive
glycoproteins. Kupffer cells, the resident liver macrophages, remove material from the
portal circulation. Kupffer cells may act both as effector cells in the destruction of
hepatocytes by producing harmful soluble mediators and as antigen-presenting cells
during viral infections of the liver. Moreover, they may represent a significant source of
chemoattractant molecules for cytotoxic CD8 and regulatory T cells. Their role in fibrosis
is well established as they are one of the main sources of transforming growth factor b1
production, which leads to the transformation of HSCs into myofibroblasts.
Figure 4 Scoring system
for chronic hepatitis C (the
Metavir Score System).
Liver biopsy remains the
gold standard to assess
fibrosis. According to the
Metavir Score System,
fibrosis is scored as F0
(absent), F1 (portal
fibrosis), F2 (portal fibrosis
with few septa), F3 (septal
fibrosis) and F4 (cirrhosis).
In addition,
necroinflammation activity
(A) is graded as A0
(absent), A1 (mild), A2
(moderate) or A3 (severe).
Recent advances in basic science
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large number of aberrant methylations involved in
the transition between normal tissue and adjacent
tissue with not further increase in cancer (ie,
MMP14, miR-219, CIDEA, etc.) or in the transition
between tissues adjacent to HCC (ie, RASFF1A,
TBX4, CA10, PTPRT, etc.).
Several studies using quantitative real-time PCR-
based methylation analysis for DNA methylation of
specific candidate genes suggest that DNA methyla-
tion is an early event preceding cirrhosis.
44–49 Other
studies suggest that some of the aberrant methyla-
tion in early-stage hepatitis is part of the normal
ageing process, chronic inflammation, iron overload
and persistent viral infections (in particular HCV).
Nishida et al report that aberrant methylation of a
limited number of loci is common in the normal
ageing liver and that these epigenetic alterations
gradually progress and expand to a larger panel of
methylation markers in HCC.
44 Moreover, they have
observed that persistent viral infection, in particular
HCV, accelerates age-related methylation in the
liver,suggestingthataberrant methylation may play
animportantroleinthegenesisofHCC.Exposureto
the major epimutagen HCV induces methylation
and causes disruption of numerous genes and
pathways during fibrinogenesis and hepatocarcino-
genesis. The pathways showing epigenetic altera-
tions in various stages of liver fibrosis (up to
cirrhosis) include: cell proliferation (p16, RIZ1/
PRDM2, HIC-1, etc.), the Wnt/b-catenin pathway
(APC, CDH1, SFRP1-4, etc.), the Ras pathway
(SPROUTY and RASSF1A), the Jak–STAT pathway
(SOCS1, SOCS3), the TGFa pathway (RUNX3)a n d
metabolism of xenobiotics (GSTP1, etc.).
The future of HCV-induced liver fibrosis
epigenomics
Although interesting biological insights and pro-
mising tools are being developed, HCV-induced
liver fibrosis epigenomics is still in its infancy. The
impact of the powerful epimutagen HCV on the
progression of aberrant methylation must be
elucidated for the different steps of liver fibrosis.
For this, comprehensive epigenomic profiling must
be performed at every step of liver fibrogenesis as
well as hepatocarcinogenesis. Gene silencing can be
viewed as an ‘‘epigenetic gatekeeper’’ step that
creates a milieu that facilitates the selection of
mutations in oncogenes and tumour suppressor
genes promoting tumour progression.
Understanding the molecular events that initiate
and maintain epigenetic gene silencing in the early
stages of HCV-associated fibrosis could help in the
development of strategies to reverse the silencing
process for the prevention and treatment of
cirrhosis and HCC.
MiRNAome AND LIVER FIBROSIS ASSOCIATED
WITH CHRONIC HCV INFECTION
Recent evidence has shown that miRNA mutations
or misexpression are associated with various human
cancers and that miRNAs can function as tumour
suppressorsandoncogenes.
50OligonucleotidemiRNA
microarrayanalysisisthemostcommonlyusedhigh-
throughput technique to assess miRNA expression
profiling (miRNAome) for a large series of sample.
The expression of a selection of a smaller number of
miRNAs can be determined by quantitative real-time
RT-PCR.
There are a few pilot studies in the literature on
miRNA expression profiling in hepatocellular
tumours, but few or none concerning HCV-
induced liver fibrosis.
The studies in HCC tissues or experimental
models of HCC have all shown that specific
miRNAs are aberrantly expressed in malignant
HCC cells or tissues compared with non-malignant
Box 3 Markers of matrix removal and matrix deposition
A stellate cell is a key cell in fibrogenesis and fibrolysis. Many pathways are
involved in hepatic stellate cell activation. These genes encode proteins involved
in extracellular remodelling, oxidative stress, signal transduction pathways, cell
cycle control, apoptosis, angiogenesis, interferon signalling, the immune
response, and so forth.
Table 1 List of the top 11 genes that differ between moderate fibrosis (F2) and mild
fibrosis (F1)
18
Gene symbol Family Name of the encoded protein
KRT19 Extracellular matrix Keratin 19
COL1A1 Extracellular matrix Collagen, type I, alpha 1
STMN2/SCG10 Cytoskeleton Stathmin-like 2
CXCL6 Cytokine Chemokine (C-X-C motif) ligand 6
CCR2 Growth factor receptor Chemokine (C-X-C motif) receptor 2
TIMP1 Inhibitor of matrix protease Tissue inhibitor 1 of matrix metalloproteinase
IL8 Interleukin Interleukin 8
IL1A Interleukin Interleukin 1 alpha
ITGA2 Cell adhesion and cell junction Integrin alpha 2
CLDN4 Cell adhesion and cell junction Claudin 4
IL2 Interleukin Interleukin 2
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51–53 Thus these miRNAs may provide
insight into cellular processes involved in carcino-
genesis or be markers of malignancy. The first
miRNAs shown to be increased (miR-21 and miR-
224) or decreased (miR-199a and miR-122a) in
HCC must be confirmed in a large series of
tumours. Several of these miRNAs have been
shown to target specific genes directly in liver
tissue—that is, miR-21 regulates PTEN,
52 miR-122a
regulates cyclin G1,
53 while miR-221 controls p57/
CDKN1C and p27/CDKN1B.
54 It is also important
to note that some miRNA genes (such as miR-1)
undergo methylation-mediated regulation in HCC
cell lines,
55 suggesting a strong link between the
DNA methylome and the miRNAome.
Interestingly, the miRNA expression profiles differ
between malignant hepatocytes, malignant cho-
langiocytes
56 and benign liver cancer,
57 suggesting
that miRNA profiling could be used as molecular
diagnostic markers in liver disease.
Although there are few studies in the literature
on miRNA genes and HCV-induced liver fibrosis,
we hypothesise that miRNAs play a critical role in
HCV infection, in the progression of fibrosis and in
the prediction of treatment response. Jiang et al
suggest that important changes in miRNA expres-
sion occur during the development of chronic viral
hepatitis and cirrhosis.
58
RESPONSE TO TREATMENT
Existing predictive factors of response to treatment
A sustained virological response (SVR) rate of
,55% is obtained with the combination of
pegylated IFNs (PEG-IFNs) and ribavirin.
59–62
Long-term follow-up studies showed that an SVR
is generally associated with clinical and histological
improvement and eradication of HCV infection in
most patients.
63
Since a significant number of patients will fail to
respond to treatment, or have a virological relapse
or significant side effects so that treatment must be
stopped, it is important to identify non-responding
patients as early as possible and ideally at baseline
(before treatment) both for patient welfare and for
cost-effectiveness. The probability of an SVR
essentially depends on genotype. Younger age,
female gender, mild fibrosis and low viral load are
also associated with a better response rate, but to a
lesser extent. In patients with HCV genotypes 2 or
3, the SVR rates reach 80%; in genotype 1 patients
the SVR rate is 50%.
An early virological response is the best pre-
dictive factor of an SVR.
60 A reduction in HCV
RNA serum levels by ,2 log10 copies/ml after the
first 12 weeks of treatment compared with base-
line is clearly associated with almost no chance of
an SVR (negative predictive value, 97–100%). A
rapid virological response (undetectable HCV RNA
at week 4) seems to be the best predictor of
treatment outcome in patients with chronic
hepatitis C.
64
Large-scale and genome-wide association studies,
and response to treatment
Hwang and colleagues have used this method to
look at the genetic differences that were associated
with IFN/ribavirin responses in 317 Taiwanese
patients with chronic hepatitis C.
65 The panel of 26
SNPs in seven genes associated with treatment
responsiveness (ADAR, CASP5, FGF1, ICSBP1,
IFI44, TAP2 and TGFBRAP1) was used to construct
Box 4 Epigenomics
Human tumours undergo a massive overall loss of DNA methylation, but also
acquire specific patterns of hypermethylation at certain promoters. In addition,
these DNA methylation changes are linked with the presence of an aberrant
pattern of histone modification. Unlike genetic alterations such as single-base
mutations or deletions, epigenetic changes are potentially reversible.
DNA methylation changes are the most widely epigenetic modifications studied
in humans. DNA methylation, the addition of a methyl group to the fifth carbon
position of the cytosine residue, occurs in the CpG dinucleotides; 3–6% of all
cytosines are methylated in normal human DNA. Potentially methylatable CpG
dinucleotides are not randomly distributed in the human genome; instead, CpG-
rich regions known as CpG islands, which span the 59 end region (promoter,
untranslated region and exon 1) of many genes, are usually unmethylated in
normal cells. This unmethylated status corresponds with the ability of CpG island-
containing genes to be transcribed in the presence of the necessary transcription
factors. In cancer cells, the transcriptional silencing of tumour suppressor genes
by CpG island promoter hypermethylation is key to the tumourigenic process.
DNA methylation occurs in a complex chromatin network and is influenced by the
modification of histone structure. Histones are no longer considered to be simple
‘‘DNA-packaging’’ proteins; they are recognised as being dynamic regulators of
gene activity that undergo many post-translational chemical modifications,
including acetylation, methylation, phosphorylation, ubiquitylation and sumoyla-
tion. The status of acetylation and methylation of specific lysine residues
contained within the tails of nucleosomal core histones is known to have a crucial
role in regulating chromatin structure and gene expression, and is commonly
disrupted in cancer cells.
Recent studies indicated that epigenetic alterations might initiate the expansion
of premalignant cells during the early stages of tumourigenesis. During the early
steps of development of the principal tumour types, such as colon, lung and
prostate, but also liver tumours, a subset of these premalignant cells undergo
subsequent irreversible genetic alterations that allow them to mediate tumour
growth.
41 Strategies to reverse epigenetic alterations might therefore be useful in
cancer prevention and treatment.
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sensitivity and the specificity of the model were
68.2% and 60.7%, respectively. Nonetheless, there
are several weaknesses in the logistic regression
approach. First, it cannot detect complex gene–
gene interactions since, like other traditional
regression methods, it relies on the basic assump-
tion of linear combinations only. Secondly, the
rapid increase in the availability of large numbers
of genetic markers increases the number of
potential predictors considerably, which, when
combined with the significantly smaller number
of observations, creates a statistical problem called
the ‘curse of dimensionality’.
66 Therefore, higher
order computational methods are needed to select
a small group of predictors and/or interactions
between predictors with a significant effect on the
trait of interest from the numerous genetic and
environmental predictors
Several ‘‘machine learning’’ approaches that
have recently been applied to investigate potential
gene–gene and gene–environment interactions in
IFN treatment or in the risk of developing cirrhosis
have been highly successful for modelling the
relationship between combinations of polymorph-
isms and clinical endpoints.
36 67–69
Lin et al used an artificial neural network (ANN)
to address gene–gene and gene–environment inter-
actions in antiviral treatment response for 523
patients with chronic hepatitis C who had received
IFN and ribavirin combination treatment, includ-
ing 350 sustained responders and 173 non-respon-
ders.
68 They focused on candidate genes involved in
pathways related to IFN signalling and immuno-
modulation. A total of 20 SNPs were selected from
six candidate genes (ADAR, CASP5, ICSBP1, IFI44,
PIK3CG and TAP2). A feedforward neural network
was used to model the responsiveness of IFN, and
the back-propagation algorithm was used for the
learning scheme. Inputs were genetic and clinical
factors including SNP markers, viral genotype, viral
load, age and gender. Outputs were the IFN-
responding status. The prediction accuracy of each
model was estimated using a fivefold cross-valida-
tion procedure, and a permutation test was applied
to measure the statistical significance of an
association between predictors and drug response.
All possible combinations of N factors were
evaluated sequentially and the N-factor model
displaying the highest prediction accuracy was
retained. IFI44 was found in the significant two-
locus, three-locus and four-locus gene–gene effect
models as well as in the significant two-factor and
three-factor gene–environment effect models.
Furthermore, viral genotype remained in the best
two-factor, three-factor and four-factor gene–
environment models. Thus, these results strongly
support the hypothesis that viral genotype and
IFI44, a member of the family of IFN-inducible
genes, play a role in the pharmacogenomics of IFN
treatment. In addition, this approach identified a
panel of 10 factors that may be more significant
than the others for further investigation. Hence,
theses results suggest that an ANN-based approach
may be useful to analyse the complex non-linear
relationship between genetic and clinical factors
and the responsiveness of IFN. Similarly, a support
vector machine (SVM) algorithm was applied to
build a tool to predict responsiveness to IFNa–
ribavirin combination treatment using host poly-
morphisms and viral genotype.
69 These authors
concluded that the SVM algorithm is a promising
method to evaluate the complex non-linear rela-
tionship between factors and successful treatment
to predict response to IFNa.
Another study genotyped eight SNPs spanning
the entire IFNc gene in two cohorts and assessed
the association between those polymorphisms and
treatment response or spontaneous viral clear-
ance.
70 The first cohort was composed of 284
patients with chronic hepatitis C who had received
IFNa-based treatment and the second comprised
251 intravenous drug users who had either
spontaneously cleared HCV or become chronically
infected. An SNP variant located in the proximal
IFNc promoter region next to the binding motif of
heat shock transcription factor (HSF), –764G, was
significantly associated with SVR. The association
was independently significant in multiple logistic
regression (p=0.04) along with race, viral load and
genotype. This variant was also significantly
associated with spontaneous recovery in the
second cohort. Functional analyses show that the
G allele confers a two- to threefold higher promoter
activity and stronger binding affinity for HSF1
than the C allele. This study suggests that the IFNc
promoter SNP –764G/C is functionally important
in determining viral clearance and treatment
response in HCV-infected patients.
Liver molecular signature of response
Liver gene expression profiling has recently been
applied to chronic hepatitis C to determine
response to treatment. Knowledge of the antiviral
mechanisms of IFN is crucial for the discovery of
new treatment response markers (fig 1). In a recent
study, expression profiling was performed on
percutaneous needle liver biopsy specimens taken
before treatment.
71 Gene expression levels were
compared in 15 non-responder, 16 responder and
20 normal liver biopsy specimens. The authors
identified 18 genes whose expression differed
significantly between all responders and all non-
responders. Many of these 18 genes are IFN
sensitive, and two (ISG15/USP18) are linked in a
novel IFN regulatory pathway, suggesting a
possible rationale for treatment resistance. In
another study, liver tissue samples were analysed
by microarray prior to treatment by IFN or IFN/
ribavirin.
72 In the IFN group, the differentially
expressed genes were mainly IFN-, lipid metabo-
lism-, complement- and oxidoreductase-related
genes. In the IFN/ribavirin combination group, a
different set of genes was identified with cyclo-
philin A and multidrug resistance protein.
In a recent study, a selection of genes associated
with liver gene expression dysregulation during
HCV infection was studied by large-scale RT-PCR
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73
Supervised class prediction analysis identified a
two-gene (IFI27 and CXCL9) signature, which
accurately predicted treatment response in 79.3%
(23/29) of patients from the validation set (Group
B), with a predictive accuracy of 100% (9/9) and of
70% (14/20) in non-responders and sustained
virological responders, respectively. The expression
profiles of responder–relapsers did not differ
significantly from those of non-responders and
sustained virological responders, and 73% (8/11) of
them were predicted as sustained virological
responders with the two-gene classifier. In conclu-
sion, non-responders and sustained virological
responders have different gene expression profiles
prior to treatment. The most notable changes in
gene expression were mainly observed in the IFN-
stimulated genes (table 2). We were able to predict
treatment response with a two-gene signature
(IFI27 and CXCL9) in two independent groups of
patients (training and validation set). Most relap-
sers clustered with sustained virological respon-
ders. Interestingly, the baseline liver levels of
expression of IFN-stimulated genes were higher in
non-responderss than in sustained virological
responders. The failure to respond to exogenous
PEG-IFN in non-responders could indicate a
blunted response to IFN. This suggests that IFN-
stimulated genes are already maximally induced in
non-responderss. Genes included in the signature
encode molecules secreted in the serum and
provide a logical functional approach for the
development of serum markers to predict response
to treatment.
One study analysed gene expression patterns in
peripheral blood mononuclear cells during IFN
treatment and confirmed upregulation of genes
thought to be IFN-stimulated genes or involved in
antigen processing and presentation.
74 However,
studies assessing gene expression in peripheral
blood mononuclear cells in chronic hepatitis C
are lacking.
Interestingly, data in HCV-infected chimpanzees
indicate a predominantly defective hepatic
response to IFN, which is probably mediated
through the activation of SOCS3 and may explain
the lack of response to IFN-based treatment in
many HCV patients.
75 Furthermore, an association
study tested three SNPs of SOCS3 in 162 non-
responders and 184 sustained responders (SOCS3 –
8464 A/C (rs12952093), –4874 A/G (rs4969170)
and 1383 A/G, (rs4969168)).
76 SOCS3 basal expres-
sion levels were significantly increased in two
independent sets of non-responder groups. The
SOCS3 –4874 AA genotype was strongly asso-
ciated with antiviral treatment failure, and AA
genotype carriers had significantly higher SOCS3
mRNA and protein levels
The diversity of microarray platforms utilised for
gene expression analysis and the variability in
microarray data emphasise the need for quality
assurance. High quality RNA samples are essential
for gene expression analysis, and the quality of
each RNA preparation must be rigorously assessed.
Careful measures must be taken during all steps of
the RNA extraction to prevent the RNA from
degrading. Furthermore, improved analytical pro-
cedures and the use of large numbers of patients
are needed for validation. Gene signatures will
probably be used in the future for optimised and
tailored treatment.
Many of the genes found to be upregulated
between non-responders and responders encode
molecules secreted in the serum (cytokines) and are
a logical functional approach for the development
of serum markers as predictors of response to
treatment. For instance, one study examined the
levels of chemokines that bind to CXC chemokine
receptor 3 (CXCR3) to determine whether they
play a role in the failure of the immune system to
clear HCV infection.
77 Levels of CXCL10 and
CXCL9 decreased during successful antiviral treat-
ment; CXCL11 did not decrease significantly
during treatment or in the first 6 months after
treatment. Baseline levels of CXCL10 were highest
in HCV patients who did not respond to treat-
ment. These results suggest that plasma concen-
trations of immunoreactive CXCL10 may be a
predictor of response to PEG-IFN with or without
ribavirin. It should be noted that we identified
CXCL9 in our two-gene signature, and that
CXCL9, CXCL10 and CXCL11 have the same
specific receptor CXCR3.
73
THE PROTEOME IN DIAGNOSTIC AND TREATMENT
Characterisation of the liver and serum proteomes
is the next step in the investigation of patients
with liver diseases since protein signatures are a
potentially powerful tool in the diagnosis and
prognosis of patients with HCV infection.
Although there are several studies describing global
gene expression changes associated with HCV
infection, changes in the proteome have not been
extensively characterised. Proteomics uses a com-
bination of sophisticated techniques including 2D
gel electrophoresis, image analysis, mass spectro-
metry, amino acid sequencing and bioinformatics.
78
A major hurdle when studying proteins is the
potentially enormous number of proteins present
in a biological sample. This diversity is due to the
Table 2 List of the genes that differ between non-responders and sustained virological
responders (training set)
73
Gene symbol Family Name of the encoded protein NR/SVR
IFI-6-16 IFN-inducible protein IFNa-inducible protein 3 3.5
IFI27 IFN-inducible protein IFNa-inducible protein 27 4.2
ISG15 IFN-inducible protein IFNa-inducible protein 2 3.7
MX1 IFN-inducible protein Activating transcription factor 6 2.7
HERC5 IFN-inducible protein Hect domain and RLD 5 2.2
TGFB2 Growth factor Transforming growth factor b2 2.7
OAS2 IFN-inducible protein 29-59-Oligoadenylate synthetase 2 1.8
VEGFD Angiogenesis Vascular endothelial growth factor D 2.4
IL8 Interleukin Interleukin 8 3.2
IFIT1 IFN-inducible protein IFN-induced protein with tetratricopeptide
repeats 1
55.3
Gene expression ratios were compared among non-responder and sustained virological responder liver gene
expression values.
IFN, interferon.
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modifications that proteins can display. Another
difficulty is the wide range of concentrations of
highly represented proteins and the low concentra-
tion of potential biomarkers. Without specific
protein amplification techniques such as PCR for
nucleic acids, the identification of biomarkers
requires technologies which have not yet been
fully validated. However, there are several good
reasons to focus on protein analysis: (1) the level of
mRNA expression does not often parallel the
amount of protein; (2) study of the genome does
not address dynamic cell processes; and (3) recent
improvements in proteomic technologies, such as
proteomic profiling technology, provide global
visualisation of the proteome by a high-throughput
method and lead to the identification of isolated or
clustered peaks associated with a disease in a
complex biological sample.
There are very few studies in the literature
addressing proteomic changes in hepatitis C. Jacobs
et al provide a global proteome analysis of changes
induced by HCV infection by multidimensional
liquid chromatographic separation coupled with
mass spectrometry in the full-length HCV replicon
model.
79 Several proteins involved in lipid biosynth-
esis were found to be upregulated, while proteins
involved in fatty acid oxidation were downregu-
lated. Some of these proteins were also found to be
deregulated in liver biopsies of patients with
chronic HCV infection. These data support the
suggested relationship between HCV and lipid
metabolism, although the physiopathological rele-
vance of these data needs to be investigated
further.
Liver fibrosis and cirrhosis are the consequences
of chronic HCV infection. They are characterised
by marked modifications of proteins including
synthesis of extracellular matrix proteins, suggest-
ing that proteomics might provide new insights for
diagnosis of fibrosis or cirrhosis. Several studies
have been performed to characterise protein
changes in tissues in experimental models of liver
fibrosis. For instance, several proteins that are
significantly deregulated during liver fibrosis have
been identified by 2D gel electrophoresis and mass
spectrometry.
80 Using similar experimental animal
models and culture of hepatic stellate cells (HSCs),
Kristensen et al compared proteomic dynamics in
in vitro and in vivo processes of HSC activation.
81
The expression of 43 proteins was shown to be
altered by 2D gel electrophoresis, when the cells
were activated in vivo and/or in vitro. Among
them, 27 displayed similar changes in vivo and in
vitro, including two members of the S100 protein
family (calcyclin and calgizzarin) and galectin-1 (a
galactosidase-binding lectin) involved in growth
regulation and neoplastic transformation.
To date, few studies have focused on serum
protein changes during the development of liver
fibrosis. In thioacetamide-induced liver fibrosis, Xu
et al showed that expression of 59 protein spots
significantly changed upon thioacetamide admin-
istration and that a protein of 3.495 kDa, sharing
homology with a histidine-rich glycoprotein, was
consistently decreased in sera of cirrhotic rats.
82 In
addition, in one study, Poon et al tried to define
serum protein signatures associated with various
degrees of fibrosis and develop a proteomic
fingerprinting model for predicting fibrosis and
cirrhosis in patients with chronic hepatitis B
infection.
83 For this purpose, they developped
ANN models to generate an ANN fibrosis index
based on the proteomic data obtained by
ProteinChip Array with laser desorption-ionisation
time of flight mass spectrometry (SELDI-TOF-MS
ProteinChip technology). SELDI-TOF provides
rapid protein profiles and comparative analyses
according to patient phenotype.
83 This approach
takes advantage of an initial fractionation step of
the proteome according to fixation on different
affinity surfaces, followed by desorption and time-
of-flight analysis of retained proteins. This techni-
que has several advantages such as being easy to
use and high throughput, making it compatible
with clinical proteomics. Thirty protein changes
were defined that were significantly associated
with the extent of liver fibrosis.
83 Interestingly,
some of these protein peaks were correlated with
biological data exploring liver function, such as
albumin. Finally, this study showed that the ANN
fibrosis index derived from the serum proteomic
fingerprint predicts patients with significant fibro-
sis and cirrhosis. Using the same approach, we
demonstrated that antiviral treatment induced
chronological changes in the serum proteome and
that these variations were dependent upon virolo-
gical response to treatment.
84 Moreover, serum
proteome analysis in naive patients predicted SVR
to PEG-IFN plus ribavirin in most of our patients.
Molecular identification of the peaks isolated by
the SELDI-TOF approach would be of major
interest for developing serum tests for patient care.
Although these global approaches are quite effec-
tive and are well adapted to clinical proteomics.
they have several limitations including the difficult
molecular identification of protein peaks and the
necessity for further analysis based on purification,
peptide fingerprinting and MS/MS sequencing.
This is the major limitation of global proteomics
analyses at present.
CONCLUSION
In addition to viral and environmental behavioural
factors, host genetic diversity is believed to play a
role in each step of the different clinical outcomes
in HCV infection (clearance of acute infection,
progression of fibrosis and treatment outcome).
The sequencing of the human genome, together
with the development of high-throughput tech-
nologies that identify gene function, have provided
unique opportunities to develop profiles to distin-
guish, identify and classify discrete subsets of the
disease, predict disease outcome or predict response
to treatment. Multiplexed protein measurement
(such as flow cytometric microbead assays using
Luminex technology) is a rapidly advancing field
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transform clinical diagnostic in the next 10 years.
In the near future, further studies must meet
several challenges: first, studies with large prospec-
tive cohorts with well phenotyped patients are
needed. For instance, in the studies evaluating the
severity of the disease, the stage of fibrosis (scoring
systems for histological fibrosis) must be carefully
determined, taking into account the duration of
HCV infection. For response to treatment, studies
must use the same definition of SVR and the same
treatment regimen. Statistical analysis must take
into account all factors associated with fibrosis
progression or response to treatment. Secondly,
technologies must be improved for routine use. For
instance, the diversity of microarray platforms
used for gene expression analysis and the varia-
bility in microarray data emphasise the need for
quality control. Careful measures must be taken
during all steps of RNA extraction to prevent the
RNA from degrading. Furthermore, analytical
procedures must be improved and large numbers
of patients must be studied for validation. Gene
signatures will probably be used in the future for
personalised medicine (optimised and tailored
treatment).
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